Advertisement

Infection

pp 1–9 | Cite as

Active surveillance of antibiotic resistance patterns in urinary tract infections in primary care in Switzerland

  • Andreas PlateEmail author
  • Andreas Kronenberg
  • Martin Risch
  • Yolanda Mueller
  • Stefania Di Gangi
  • Thomas Rosemann
  • Oliver Senn
Original Paper
  • 120 Downloads

Abstract

Purpose

Urinary tract infections (UTI) are one of the most common reasons for prescribing antibiotics in primary care. In Switzerland, the Swiss Center for Antibiotic Resistances (ANRESIS) provides resistance data by passive surveillance, which overestimates the true resistance rates. The aim of this study was to provide actual data of the antimicrobial resistance patterns in patients with UTI in Swiss primary care.

Methods

From June 2017 to August 2018, we conducted a cross-sectional study in 163 practices in Switzerland. We determined the resistance patterns of uropathogens in patients with a diagnosis of a lower UTI and analyzed risk factors for resistance. Patients with age < 18 years, pregnancy or a pyelonephritis were excluded.

Results

1352 patients (mean age 53.8, 94.9% female) were included in the study. 1210 cases (89.5%) were classified as uncomplicated UTI. Escherichia coli (E. coli) was the most frequent pathogen (74.6%). Susceptibility proportions of E. coli to ciprofloxacin (88.9%) and trimethoprim-sulfamethoxazol (TMP/SMX) (85.7%) were significantly higher than the proportions reported by ANRESIS. We found high susceptibility to the recommended first-line antibiotics nitrofurantoin (99.5%) and fosfomycin (99.4%). Increasing age, antimicrobial exposure and a recent travel history were independently associated with resistance.

Discussion

In this study, we report actual data on the resistance patterns of uropathogens in primary care in Switzerland. Escherichia coli showed low resistance rates to the recommended first-line antibiotics. Resistance to TMP/SMX was significantly lower than reported by ANRESIS, making TMP/SMX a suitable and cheap alternative for the empirical treatment.

Keywords

Urinary tract infection Resistance rates Susceptibility rates E. coli Primary care Switzerland 

Notes

Acknowledgements

We wish to thank primary care physicians and patients that participated in the study; we acknowledge Swiss family medicine institutes in Geneva, Lausanne, Lucerne, Basel and Zürich, the representatives of the local medical networks that supported recruitment of family physicians and the anresis-laboratories for sharing their data; we acknowledge Dr. phil. II Michael Ritzler und Dr. scient. med. Nadia Wohlwend as well as all involved laboratory members of the laboratory Risch, which performed all urine analysis for this study.

Funding

This study was supported by grants from SwissLife, Blumenau-Léonie Hartmann Foundation, and Innova Foundation. ANRESIS is funded by the Swiss federal office of public health and the University of Bern. They had no influence over the study design, study results, interpretation of the data and publication.

Compliance with ethical standards

Conflict of interest

All authors declare no conflict of interest.

Supplementary material

15010_2019_1361_MOESM1_ESM.docx (34 kb)
Supplementary material 1 (DOCX 33 kb)

References

  1. 1.
    Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010;7:653–60.  https://doi.org/10.1038/nrurol.2010.190.CrossRefPubMedGoogle Scholar
  2. 2.
    Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002;113:5s–13s.CrossRefGoogle Scholar
  3. 3.
    Petersen I, Hayward AC. Antibacterial prescribing in primary care. J Antimicrobi Chemother. 2007;60:i43–7.  https://doi.org/10.1093/jac/dkm156.CrossRefGoogle Scholar
  4. 4.
    Ikaheimo R, Siitonen A, Heiskanen T, Karkkainen U, Kuosmanen P, Lipponen P, et al. Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis. 1996;22:91–9.CrossRefGoogle Scholar
  5. 5.
    Falagas ME, Kotsantis IK, Vouloumanou EK, Rafailidis PI. Antibiotics versus placebo in the treatment of women with uncomplicated cystitis: a meta-analysis of randomized controlled trials. J Infect. 2009;58:91–102.  https://doi.org/10.1016/j.jinf.2008.12.009.CrossRefPubMedGoogle Scholar
  6. 6.
    Kronenberg A, Butikofer L, Odutayo A, Muhlemann K, da Costa BR, Battaglia M, et al. Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. BMJ (Clin Res ed). 2017;359:j4784.  https://doi.org/10.1136/bmj.j4784.CrossRefGoogle Scholar
  7. 7.
    Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for microbiology and infectious diseases. Clin Infect Dis. 2011;52:e103–20.  https://doi.org/10.1093/cid/ciq257.CrossRefPubMedGoogle Scholar
  8. 8.
    Hasse B, Egger M, Zanetti G, Marschall J, Mühlemann K, Harbarth S. Behandlung von unkomplizierten Harnwegsinfektionen. 2014.Google Scholar
  9. 9.
    Swiss Centre for Antibiotic resistance. 2018. http://www.anresis.ch. Accessed 23 Sept 2018.
  10. 10.
    Kronenberg A, Koenig S, Droz S, Muhlemann K. Active surveillance of antibiotic resistance prevalence in urinary tract and skin infections in the outpatient setting. Clin Microbiol Infect. 2011;17:1845–51.  https://doi.org/10.1111/j.1469-0691.2011.03519.x.CrossRefPubMedGoogle Scholar
  11. 11.
    Hooton TM. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med. 2012;366:1028–37.  https://doi.org/10.1056/nejmcp1104429.CrossRefPubMedGoogle Scholar
  12. 12.
    Klingeberg A, Noll I, Willrich N, Feig M, Emrich D, Zill E, et al. Antibiotic-resistant E. coli in uncomplicated community-acquired urinary tract infection. Deutsches Arzteblatt Int. 2018;115:494–500.  https://doi.org/10.3238/arztebl.2018.0494.CrossRefGoogle Scholar
  13. 13.
    Filippini M, Masiero G, Moschetti K. Socioeconomic determinants of regional differences in outpatient antibiotic consumption: evidence from Switzerland. Health policy (Amsterdam, Netherlands). 2006;78:77–92.  https://doi.org/10.1016/j.healthpol.2005.09.009.CrossRefGoogle Scholar
  14. 14.
    Achermann R, Suter K, Kronenberg A, Gyger P, Muhlemann K, Zimmerli W, et al. Antibiotic use in adult outpatients in Switzerland in relation to regions, seasonality and point of care tests. Clin Microbiol Infect. 2011;17:855–61.  https://doi.org/10.1111/j.1469-0691.2010.03348.x.CrossRefPubMedGoogle Scholar
  15. 15.
    Pluss-Suard C, Pannatier A, Kronenberg A, Muhlemann K, Zanetti G. Hospital antibiotic consumption in Switzerland: comparison of a multicultural country with Europe. J Hosp Infect. 2011;79:166–71.  https://doi.org/10.1016/j.jhin.2011.05.028.CrossRefPubMedGoogle Scholar
  16. 16.
    Hooton TM, Besser R, Foxman B, Fritsche TR, Nicolle LE. Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy. Clin Infect Dis. 2004;39:75–80.  https://doi.org/10.1086/422145.CrossRefPubMedGoogle Scholar
  17. 17.
    ECDC. Surveillance of antimicrobial resistance in Europe 2017. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2017.Google Scholar
  18. 18.
    Wagenlehner FM, Naber KG. Current challenges in the treatment of complicated urinary tract infections and prostatitis. Clin Microbiol Infect. 2006;12:67–80.  https://doi.org/10.1111/j.1469-0691.2006.01398.x.CrossRefPubMedGoogle Scholar
  19. 19.
    Peterson J, Kaul S, Khashab M, Fisher A, Kahn JB. Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006. Clin Ther. 2007;29:2215–21.  https://doi.org/10.1016/j.clinthera.2007.10.008.CrossRefPubMedGoogle Scholar
  20. 20.
    Hitzenbichler F, Simon M, Holzmann T, Iberer M, Zimmermann M, Salzberger B, et al. Antibiotic resistance in E. coli isolates from patients with urinary tract infections presenting to the emergency department. Infection. 2018;46:325–31.  https://doi.org/10.1007/s15010-018-1117-5.CrossRefPubMedGoogle Scholar
  21. 21.
    Almomani BA, Hayajneh WA, Ayoub AM, Ababneh MA, Al Momani MA. Clinical patterns, epidemiology and risk factors of community-acquired urinary tract infection caused by extended-spectrum beta-lactamase producers: a prospective hospital case–control study. Infection. 2018;46:495–501.  https://doi.org/10.1007/s15010-018-1148-y.CrossRefPubMedGoogle Scholar
  22. 22.
    Bonkat G, Bruyère F, Cai T, Geerlings SE, Köves B, Schubert S, Wagenlehner F. Urological infections guidelines 2018.Google Scholar
  23. 23.
    Johansen TE, Botto H, Cek M, Grabe M, Tenke P, Wagenlehner FM, et al. Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system. Int J Antimicrob Agents. 2011;38:64–70.  https://doi.org/10.1016/j.ijantimicag.2011.09.009.CrossRefPubMedGoogle Scholar
  24. 24.
    Zhanel GG, Zhanel MA, Karlowsky JA. Oral fosfomycin for the treatment of acute and chronic bacterial prostatitis caused by multidrug-resistant Escherichia coli. Can J Infect Dis Med Microbiol. 2018;2018:1404813.  https://doi.org/10.1155/2018/1404813.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Lipsky BA, Byren I, Hoey CT. Treatment of bacterial prostatitis. Clin Infect Dis. 2010;50:1641–52.  https://doi.org/10.1086/652861.CrossRefPubMedGoogle Scholar
  26. 26.
    Tenney J, Hudson N, Alnifaidy H, Li JTC, Fung KH. Risk factors for acquiring multidrug-resistant organisms in urinary tract infections: a systematic literature review. Saudi Pharm J. 2018;26:678–84.  https://doi.org/10.1016/j.jsps.2018.02.023.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Garau J, Xercavins M, Rodriguez-Carballeira M, Gomez-Vera JR, Coll I, Vidal D, et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother. 1999;43:2736–41.CrossRefGoogle Scholar
  28. 28.
    Alós JI, Serrano MG, Gómez-Garcés JL, Perianes J. Antibiotic resistance of Escherichia coli from community-acquired urinary tract infections in relation to demographic and clinical data. Clin Microbiol Infect. 2005;11:199–203.  https://doi.org/10.1111/j.1469-0691.2004.01057.x.CrossRefPubMedGoogle Scholar
  29. 29.
    Ukah UV, Glass M, Avery B, Daignault D, Mulvey MR, Reid-Smith RJ, et al. Risk factors for acquisition of multidrug-resistant Escherichia coli and development of community-acquired urinary tract infections. Epidemiol Infect. 2018;146:46–57.  https://doi.org/10.1017/S0950268817002680.CrossRefPubMedGoogle Scholar
  30. 30.
    Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N, et al. Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial. Effect of nitrofurantoin vs fosfomycin on uncomplicated lower UTI in women. Effect of nitrofurantoin vs fosfomycin on uncomplicated lower UTI in women. JAMA. 2018;319:1781–9.  https://doi.org/10.1001/jama.2018.3627.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Institute of Primary CareUniversity and University Hospital of ZurichZurichSwitzerland
  2. 2.Swiss Center for Antibiotic Resistance, Institute for Infectious DiseasesUniversity Bern, Bern and Medix General Practice NetworkBernSwitzerland
  3. 3.Labormedizinisches zentrum Dr Risch Ostschweiz AGSt. GallenSwitzerland
  4. 4.Department of Family Medicine, Center for Primary Care and Public Health (Unisanté)University of LausanneLausanneSwitzerland

Personalised recommendations